Here are the S-1 registration statements from Fortress Biotech, Inc. (FBIO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow FBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FBIO filings page.
Fortress Biotech, Inc. is registering up to 600,000 shares of common stock for potential resale by Oaktree-affiliated selling stockholders. These shares are issuable upon exercise of warrants granted under a December 12, 2025 amendment to Fortress’s senior credit agreement, with an exercise price of $2.62 per share and an expiration date of July 25, 2031. The warrants became immediately exercisable and include anti-dilution adjustments and an option for net exercise without cash payment.
Fortress’s common stock trades on the Nasdaq Capital Market under the symbol FBIO, and the last reported sale price on December 11, 2025 was $2.94 per share. There were 31,037,937 shares outstanding as of that date, which would rise to 31,637,937 shares if all 600,000 warrant shares were issued. Fortress will not receive any proceeds from the resale of these shares but will cover registration expenses, while investors are referred to the company’s incorporated risk factor disclosures for a detailed discussion of risks.